SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced regulatory approvals in select international markets.
Obalon has received notification that it has obtained the necessary regulatory approvals in select Middle East markets to commercialize the Obalon six-month balloon and the associated inflation dispenser. Obalon intends to fulfill an initial order to its Middle East distributor, Bader Sultan, during the second quarter of 2017.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 email@example.com Media: Megan Driscoll EvolveMKD Office Phone: +1 646 517 4220 firstname.lastname@example.org
Source:Obalon Therapeutics, Inc.